Nationwide antibiogram analysis using NCCLS M39-A guidelines

Journal of Clinical Microbiology

Volumn 43, Issue 6, 2005, Pages 2629-2634

  Zapantis, Antonia ^a   Lacy, Melinda K ^b   Horvat, Rebecca T ^c   Grauer, Dennis ^b   Barnes, Brian J ^b   O'Neal, Brian ^b   Couldry, Rick ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; IMIPENEM; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG SENSITIVITY; ENTEROCOCCUS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; INTERNET; KLEBSIELLA PNEUMONIAE; NONHUMAN; POSTAL MAIL; PRACTICE GUIDELINE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; HUMANS; LABORATORIES, HOSPITAL; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES; QUALITY CONTROL; UNITED STATES;

ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; STAPHYLOCOCCUS AUREUS;

EID: 20444502169     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.6.2629-2634.2005     Document Type: Article

References (27)

1. Calfee, D. P., and B. M. Farr. 2002. Infection control and cost control in the era of managed care. Infect. Control Hosp. Epidemiol. 23:407-410.
2. Centers for Disease Control and Prevention. 2004. Campaign to prevent antimicrobial resistance in Healthcare settings [Online.] http://www.cdc.gov /drugresistance/healthcare/default.htm.
3. Centers for Disease Control and Prevention. 2003. VISA/VRSA-vancomycin- intermediate/resistant Staphylococcus aureus. Fact sheet. [Online.] http: //www.cdc.gov/ncidod/hip/ARESIST/visa.htm.
4. Ernst, E. J., D. J. Diekema, B. J. Bootsman, T. Vaughn, J. W. Yankey, S. D. Flach, M. M. Ward, C. L. J. Franciscus, E. Acosta, M. A. Pfaller, and B. N. Doebbeling. 2004. Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data? Diagn. Microbiol. Infect. Dis. 49:141-145.
5. Fridkin, S. K. 2001. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
6. Ginocchio, C. 2002. Role of NCCLS in antimicrobial susceptibility testing and monitoring. Am. J. Health Syst. Pharm. 59(Suppl. 3):S7-S11.
7. Gums. J. G. 2002. Assessing the impact of antimicrobial resistance. Am. J. Health Syst. Pharm. S9(Suppl. 3):S4-S6.
8. Halstead, D. C., N. Gomez, and Y. S. McCarter. 2004. Reality of developing a community-wide antibiogram. J. Clin. Microbiol. 42:1-6.
9. Hecker, M. T., D. C. Aron, N. P. Patel, M. K. Lehmann, and C. J. Donskey. 2003. Unnecessary use of antimicrobials in hospitalized patients. Arch. Intern. Med. 163:972-978.
10. Horvat, R. T., N. E. Klutman, M. K. Lacy, D. Grauer, and M. Wilson. 2003. Effect of duplicate isolates of methicillin-susceptible and methicillin-resistant Staphylococcus aureus on antibiogram data. J. Clin. Microbiol. 41:4611-4616.
11. Joint Commission on Accreditation of Healthcare Organizations. 2000 Comprehensive accreditation manual for hospitals: the official handbook. Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, Ill.
12. Jones, R. N. 2001. Method preferences and test accuracy of antimicrobial susceptibility testing. Arch. Pathol. Lab. Med. 125:1285-1289.
13. Kacica, M., and L. C. McDonald. 2004. Brief report: vancomycin-resistant Staphylococcus aureus-New York, 2004. Morb. Mortal. Wkly. Rep. 53:322-323.
14. Lacy, M. K., N. E. Klutman, R. T. Horvat, and A. Zapantis. 2004. Antibiograms: new NCCLS guidelines, development, and clinical application. Hosp. Pharm. 39:542-553.
15. Lamp, K. 1996. Antibiograms. Pharm. Pract. Manag. Q. 16:52-56.
16. Lee, S., Y. K. Cho, S. Kim, E. S. Lee, S. Y. Park, and Y. Seo. 2004. Comparison of trends of resistance rates over 3 years calculated from results for all isolates and for the first isolate of a given species from a patient. J. Clin. Microbiol. 41:4776-4779.
17. NCCLS. 2002. Analysis and presentation of cumulative susceptibility test data; approved guideline. NCCLS document M39-A. NCCLS, Wayne, Pa.
18. NCCLS. 2002. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement. NCCLS document M100-S12. NCCLS, Wayne, Pa.
19. Patton, K. A. 2002. Role of JCAHO standards and clinical practice guidelines in promoting appropriate antimicrobial use. Am. J. Health Syst. Pharm. 59(Suppl. 3):S16-S18.
20. Pflomm, J. 2002. Strategies for minimizing antimicrobial resistance. Am. J. Health Syst. Pharm. 59(Suppl. 3):S12-S15.
21. Rush, D. R. 1991. Antimicrobial formulary management: meeting the challenge in the community hospital. Pharmacotherapy 11(1, Pt. 2):19S-26S.
22. Shannon, K. P., and G. L. French. 2002. Antibiotic resistance: effect of different criteria for classifying isolates as duplicates on apparent resistance frequencies. J. Antimicrob. Chemother. 49:201-204.
23. Stein, C. R., D. J. Weber, and M. Kelley. 2003. Using hospital antibiogram data to assess regional pneumococcal resistance to antibiotics. Emerg. Infect. Dis. 9:211-216.
24. Ting, Y., and D. Miles. 2002. Developing a web-based tool using hospital-specific cumulative antibiogram data. Hosp. Pharm. 37:1190-1195.
25. Van Beneden, C. A., C. Lexau, W. Baughman, B. Barnes, N. Bennett, P. M. Cassidy, M. Pass, L. Gelling, N. L. Barrett, E. R. Zell, and C. G. Whitney. 2003. Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae. Emerg. Infect. Dis. 9:1089-1095.
26. Wester, C. W., L. Durairaj, A. T. Evans, D. N. Schwartz, S. Husain, and E. Martinez. 2002. Antibiotic resistance, a survey of physician perceptions. Arch. Intern. Med. 162:2210-2216.
27. White, R. L., L. V. Friedrich, D. S. Burgess, E. W. Brown, and L. E. Scott. 2001. Effect of removal of duplicate isolates on cumulative susceptibility reports. Diagn. Microbiol. Infect. Dis. 39:251-256.